Raghav Bhardwaj

Raghav Bhardwaj currently serves as a Visiting Scientist at the Broad Institute of MIT and Harvard, focusing on the metabolism program within the Type 2 diabetes systems genomics initiative under the guidance of Dr. Melina Claussnitzer. Prior experience includes a role as Associate Scientist at Avidity Biosciences, where Raghav led the development of innovative techniques for assessing siRNA toxicity and contributed to key drug candidate data for Duchenne muscular dystrophy, resulting in FDA acceptance of an Investigational New Drug application. Raghav's educational background includes a Master of Science in Biological Sciences and a Bachelor of Science in Physiology and Neuroscience from UC San Diego, where Raghav also gained teaching experience and conducted significant research at the Salk Institute for Biological Studies, focusing on time-restricted feeding and its effects on muscle function.